3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Melanoma
2
Carcinoma, Renal Cell
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Interventions
pembrolizumab
21
Nivolumab
7
Docetaxel
7
Paclitaxel
5
Magnetic Resonance Spectroscopy
5
Carboplatin
5
Trastuzumab
4
Specimen Handling
4
Psychiatric Rehabilitation
4
Cyclophosphamide
4
tisotumab vedotin
3
fludarabine
3
atezolizumab
3
Taxes
3
Polymerase Chain Reaction
3
Gene Expression Profiling
3
Gemcitabine
3
Fluorouracil
3
Counseling
3
Cisplatin
3
Albumin-Bound Paclitaxel
3
ulixertinib
2
poly ICLC
2
durvalumab
2
belinostat
2
X-Rays
2
Standard of Care
2
Radiotherapy
2
Radiation
2
Oxaliplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Interleukin-15
×
Genitourinary
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled